Summary: | Pierpaolo Di Micco,1 Manuel Monreal2 1Department of Internal Medicine and Emergency Room, Ospedale Buon Consiglio Fatebenefratelli, Naples, Italy; 2Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universidad Autónoma de Barcelona, Badalona, Barcelona, SpainCorrespondence: Pierpaolo Di Micco Email pdimicco@libero.itAbstract: Major bleeding is one of the most dangerous complications for patients undergoing anticoagulant treatment for VTE. Several clinical scores have been planned to identify patients at higher risk of bleeding, and most of them take into consideration the number of platelets in particular if lower than normal. Here we report the clinical experience made with the RIETE registry concerning anticoagulant treatment in the presence of different values of platelets and their related risk of bleeding.Keywords: thrombocytopenia, venous thromboembolism, bleeding, bleeding risk
|